From: Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease
Liver disease | MSCs source | Mechanism | Outcome | References |
---|---|---|---|---|
Liver sterile inflammatory injury | BM-MSCs | Promote Hippo signaling pathway | Shift macrophage polarization from M1 to M2 phenotype, diminish inflammatory mediators, and reduce hepatocellular damage | Li et al. [13] |
Not mentioned | BM-MSCs | Inhibit CD25 expression and LKB1-AMPK-mTOR pathway | Potentiate T cell suppression | Yoo et al. [14] |
Graft versus host disease | hP-MSCs | Regulate the crosstalk between Nrf2 and NF-κB signaling pathway | Inhibit the expression of PD-1 in CD4+ IL-10+ T cells, mitigate liver damage and improve redox metabolism | Zhang et al. [15] |
Not mentioned | BM-MSCs | Activate Notch pathway | Increase Treg induction | Rashedi et al. [16] |
Liver fibrosis | UC-MSCs | Strongly inhibit TGFβ signaling of HSCs | Inhibit HSC activation, reduce ECM deposition and liver fibrosis | An et al. [17] |
Thioacetamide-induced hepatic fibrosis | BM-MSCs | Inhibit TGF-β/Smad pathway in HSCs | Reduce hepatic collagen distribution, lowered the hydroxyproline content, and rescued liver function impairment | Jang et al. [18] |
Liver fibrosis | BM-MSCs | Activate Notch1 signaling pathway and inhibit PI3K/Akt pathway | Inhibit the proliferation of HSCs | Chen et al. [19] |
Liver fibrosis | BM-MSCs derived exosomes | Inhibit Wnt/β-catenin pathway | Inhibit HSC activation, reduce collagen accumulation, enhance liver functionality, inhibition of inflammation, and increased hepatocyte regeneration | Rong et al. [20] |